A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer

References

• Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: an overview of current options. Cancer Pract 2001; 9: 295–306.
   Google Scholar
• Rini BI, Small ET. An update on prostate cancer. Curr Opin Oncol 2001; 13: 204–11.
   PubMed Web of Science ®Google Scholar
• Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47.
   PubMed Web of Science ®Google Scholar
• Figg WD, Feuer J, Bauer KS. Management of hormone-sensitive metastatic prostate cancer. Cancer Pract 1997; 5: 258–63.
   Google Scholar
• Goktos S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26: 162–73.
   PubMed Web of Science ®Google Scholar
• Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1999; 26: 428–38.
   PubMed Web of Science ®Google Scholar
• Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-indepen- dent prostate cancer. Semin Oncol 2001; 28\(Suppl 15): 62–6 (Aug).
   Google Scholar
• Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88(Suppl 12): 3015–21.
   PubMedGoogle Scholar
• Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-beta in prostate cancer. Microsc Res Tech 2001; 52: 4 11–9.
   Google Scholar
• Barrack ER. TGF beta in prostate cancer: a growth inhi-bitor that can enhance tumorigenicity Prostate 1997; 31: 61–70.
   Google Scholar
• Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996; 2: 1255–61.
   PubMed Web of Science ®Google Scholar
• Rohlff C, Blagoskonny MV, Kyle E, et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p2 1 'a "P . Prostate 1998; 37: 5 1–9.
   PubMed Web of Science ®Google Scholar
• Ritchie GL. Current therapeutics. 218. Vinblastine in malig-nant disease. Practitioner 1966; 196: 310–5.
   Google Scholar
• Navarro M, Bellmunt J, Balana C, Colomer R, Jolis L, del Campo JM. Mitomycin-C and vinblastine in advanced breast cancer. Oncology 1989; 46: 137–42.
   Google Scholar
• Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000; 16: 89–111.
   PubMed Web of Science ®Google Scholar
• Murphy GP Review of phase II hormone refractory prostate cancer trials. Urology 1999; 54(Suppl 6A): 19–21.
   Google Scholar
• Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cacner. J Clin Oncol 1992; 10: 1754–61.
   PubMed Web of Science ®Google Scholar
• Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1999; 84: 1811–6.
   Google Scholar
• Pienta KJ, Replogle T, Lehr JE. Inhibition of prostate cancer growth by vinblastine and tamoxifen. Prostate 1995; 26: 270–4.
   Google Scholar
• Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clnical trials in androgen-independent prostate cancer: recommendations from the Pros-tate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 346 1–7 .
   PubMed Web of Science ®Google Scholar
• Agresti A. Categorical data analysis. New York: John Wiley and Sons, 1990.
   Google Scholar
• Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 1989; 62: 79–87.
   Google Scholar
• Knabbe C, Klein H, Zugmaier G, Voigt KD. Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer. J Steroid Biochem Mol Biol 1993; 47: 137–42.
   PubMed Web of Science ®Google Scholar
• Robertson KM, Penland SN, Padilla GM, et al. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth Differ 1997; 8: 101–11.
   PubMedGoogle Scholar
• Massague J. How cells read TGF-P signals. Nature 2000; 1: 169–78.
   Web of Science ®Google Scholar
• Massague J. TGF-P signal transduction. Annu Rev Biochem 1998; 67: 753–91.
   PubMed Web of Science ®Google Scholar
• Goodnight J, Mischak H, Mushinski JF Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation. Adv Cancer Res 1994; 64: 159–209.
   PubMed Web of Science ®Google Scholar
• Wilding G Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta. Cancer Surv 1991; 11: 147–63.
   PubMedGoogle Scholar
• Muir GH, Butta A, Shearer RJ, et al. Induction of transform-ing growth factor beta in hormonally treated human prostate cancer. Br J Cancer 1994; 69: 130–4.
   PubMed Web of Science ®Google Scholar
• Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL. Blockade of transforming growth factor p signaling does not abrogate antiestrogen-induced growth in-hibition of human breast carcinoma cells. J Biol Chem 1997; 272: 8296–302.
   PubMed Web of Science ®Google Scholar
• O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2462–5.
   PubMed Web of Science ®Google Scholar
• Sporn MB. New agents for chemoprevention of prostate cancer. Eur Urol 1999; 35: 420–3.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Margolis RL, Himes RH. Identification of a distinct class of vinblastine binding site on microtubules. J Mol Biol 1986; 187: 61–73.
   Google Scholar
• Bergan RC, Reed E, Myers CE, et al. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 1999; 5: 2366–73.
   PubMed Web of Science ®Google Scholar